Biology-guided deep learning predicts prognosis and cancer immunotherapy response
Yuming Jiang(Wake Forest University), Ruijiang Li(Peking University), Chuanli Chen(Nanfang Hospital), Wenjun Xiong(Jinan University), M. Usman Ahmad(Stanford University), Yikai Xu(Nanfang Hospital), Shengtian Sang(Stanford University), Zhen Han(Nanfang Hospital), Weicai Huang(Nanfang Hospital), George A. Poultsides(Stanford University), Guoxin Li(Affiliated Hospital of Jining Medical University), Yulan Ren(Stanford University), Lei Xing(North China University of Science and Technology), Zhicheng Zhang(Stanford University), Sujuan Xi(Sun Yat-sen University), Tuanjie Li(Nanfang Hospital), Wei Wang(China Medical University), Jen‐Yeu Wang(Stanford University), Qingyu Yuan(Nanfang Hospital), Jingjing Xie(University of California, Davis)
Cited by 98
Related Papers
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer
|JAMA Oncology|2017|600
Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment
|Journal of Clinical Oncology|2009|390